Source:http://linkedlifedata.com/resource/pubmed/id/16707560
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2006-6-26
|
pubmed:abstractText |
Constitutive expression of cell-associated, but not secreted, interleukin-1alpha (IL-1alpha) by oncogene-transformed fibrosarcoma cells induced regressing tumors in mice, a phenomenon that was abrogated by the IL-1 inhibitor, the IL-1 receptor antagonist (IL-1Ra). On the contrary, non-IL-1alpha-expressing tumor cells induce progressive tumors in mice. In vivo and ex vivo experiments have shown that regression of IL-1alpha-positive fibrosarcoma cells depends on CD8(+) T cells, which can also be activated in CD4(+) T cell-depleted mice, with some contribution of natural killer cells. In spleens of mice bearing the non-IL-1alpha-expressing fibrosarcoma cells, some early and transient manifestations of antitumor-specific immunity, such as activation of specific proliferating T cells, are evident; however, no development of cytolytic T lymphocytes or other antitumor protective cells could be detected. In spleens of mice bearing the non-IL-1alpha-expressing fibrosarcoma cells, the development of early tumor-mediated suppression was observed, and in spleens of mice injected with IL-1alpha-positive fibrosarcoma cells, protective immunity developed in parallel to tumor regression. Treatment of mice bearing violent fibrosarcoma tumors with syngeneic-inactivated, IL-1alpha-positive fibrosarcoma cells, at a critical interval after injection of the malignant cells (Days 5-12), induced tumor regression, possibly by potentiating and amplifying transient antitumor cell immune responses or by ablation of tumor-mediated suppression. Membrane-associated IL-1alpha may thus serve as an adhesion molecule, which allows efficient cell-to-cell interactions between the malignant and immune effector cells that bear IL-1Rs and function as a focused cytokine with adjuvant activities at nontoxic, low levels of expression. Our results also point to the potential of using antitumor immunotherapeutic approaches using cell-associated IL-1alpha.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0741-5400
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
80
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
96-106
|
pubmed:meshHeading |
pubmed-meshheading:16707560-Animals,
pubmed-meshheading:16707560-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16707560-Cell Line, Tumor,
pubmed-meshheading:16707560-Fibrosarcoma,
pubmed-meshheading:16707560-Interleukin-1alpha,
pubmed-meshheading:16707560-Mice,
pubmed-meshheading:16707560-Mice, Inbred Strains,
pubmed-meshheading:16707560-Neoplasm Regression, Spontaneous
|
pubmed:year |
2006
|
pubmed:articleTitle |
Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1alpha.
|
pubmed:affiliation |
Department of Microbiology and Immunology, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|